SCHEDULE: Vestal Point Capital Discloses 6% Stake in Lexeo
Beneficial Ownership Report
Vestal Point Capital, LP and Ryan Wilder have reported a 6.0% beneficial ownership stake in Lexeo Therapeutics, Inc.'s common stock.
Summary
- Vestal Point Capital, LP and Ryan Wilder collectively hold 3,228,161 shares of Lexeo Therapeutics, Inc. common stock.
- This represents 6.0% of the company's outstanding common stock.
- The ownership percentage is calculated based on an aggregate of 53,987,117 shares of Common Stock outstanding.
- This total includes 33,196,997 shares outstanding as of May 9, 2025, and an additional 20,790,120 shares issued on May 27, 2025, in connection with a private placement.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The filing is a standard beneficial ownership disclosure, indicating a significant institutional investment in Lexeo Therapeutics, Inc. by Vestal Point Capital, LP and Ryan Wilder. While not directly indicative of company performance, a substantial stake by an investment firm can be viewed as a positive signal of confidence.
Positives
- Vestal Point Capital, LP and Ryan Wilder have taken a significant 6.0% beneficial ownership stake in Lexeo Therapeutics, Inc., indicating institutional confidence.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership report.
Industry Context
This filing indicates a significant investment by an investment firm in a therapeutics company. Such institutional investments are common in the biotechnology and pharmaceutical sectors, where firms take positions in companies with perceived growth potential or promising pipelines.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor could be perceived positively by existing shareholders. The private placement mentioned, which increased the total shares outstanding, would have resulted in dilution for existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | 33,196,997 shares of Common Stock outstanding reported in Amendment No. 1 to the Company's Quarterly Report on Form 10-Q/A. |
| 05/15/2025 | Amendment No. 1 to the Company's Quarterly Report on Form 10-Q/A for the quarterly period ended March 31, 2025, filed with the SEC. |
| 05/27/2025 | 20,790,120 shares of Common Stock issued by the Company in connection with a private placement, as described in a Current Report on Form 8-K filed with the SEC. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 08/14/2025 | Filing date of this Schedule 13G statement. |
Keywords
Lexeo Therapeutics, Vestal Point Capital, Ryan Wilder, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Investment Adviser, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.